Loading…
Loading…
BILLERICA, Mass.--(BUSINESS WIRE)--Javelin Biotech today announced a landmark scientific publication, titled "Interconnected multi-microphysiological systems and PBPK modeling for predicting human pharmacokinetics”, in the "Breakthrough" special issue of Lab on a Chip. The study details a liver-centric multi-tissue chip (MTC) platform designed to capture the complex pharmacokinetic (PK) profiles of small-molecule drugs. The research marks a significant demonstration of how combinatorial NAMs en.
Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in w
Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demo
MMTec, Inc. (NASDAQ: MTC - Get Free Report)'s share price was down 6.9% during mid-day trading on Monday. The company traded as low as $3.20 and last traded at $3.22. Approximately 42,251 shares were traded during trading, a decline of 57% from the average daily volume of 98,074 shares. The stock had previously closed at
HONG KONG , Dec. 11, 2025 /PRNewswire/ -- MMTEC, Inc. (NASDAQ: MTC) ("MMTEC", "we", "our" or the "Company"), a China-based technology company that provides access to the U.S. financial markets, today announced that on December 9, 2025, the Company received a decision letter (the "Decision Letter") from the Nasdaq Hearings Panel of The Nasdaq Stock Market LLC ("Nasdaq"). The Company previously received a determination letter (the "Determination Letter") which advised that for the 30 consecutive business days prior to the date of the Determination Letter the minimum closing bid price per share for the Company's common stock was below the $1.00 per share requirement for continued listing under Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule").
HONG KONG , Oct. 28, 2025 /PRNewswire/ -- MMTEC, Inc. (NASDAQ: MTC) ("MMTEC", "we", "our" or the "Company"), a China-based technology company that provides access to the U.S. financial markets, today announced that on October 27, 2025, the Company received a determination letter (the "Determination Letter") from the Listings Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") regarding a failure to meet Nasdaq's minimum bid price requirements. The Determination Letter advised that for the last 30 consecutive business the minimum closing bid price per share for the Company's common stock was below the $1.00 per share requirement for continued listing under Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule").
HONG KONG , Dec. 12, 2024 /PRNewswire/ -- MMTEC, Inc. ("MMTEC" or the "Company") (Nasdaq: MTC) reported that it expects to implement a 1-for-8 reverse stock split on its common stock. The effective date is scheduled to be December 18, 2024, subject to the Company's satisfaction of Nasdaq Operations notice requirements, with trading to begin on a split-adjusted basis at the market open on that day.
HONG KONG , July 10, 2024 /PRNewswire/ -- MMTEC, Inc. (NASDAQ: MTC) ("MMTEC", "we", "our" or the "Company"), a China-based technology company that provides access to the U.S. financial markets, today announced that on July 8, 2024, the Company received a notification letter (the "Notification Letter") from the Listings Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") regarding a failure to meet Nasdaq's minimum bid price requirements. The Notification Letter advised that for the last 30 consecutive business the minimum closing bid price per share for the Company's common stock was below the $1.00 per share requirement for continued listing under Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule").